Format

Send to

Choose Destination
Transplantation. 2018 Mar;102(3):478-483. doi: 10.1097/TP.0000000000001985.

Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate.

Author information

1
Department of Medicine, Mayo Clinic, Phoenix, AZ.
2
Department of Health Science Research, Mayo Clinic, Rochester, MN.

Abstract

BACKGROUND:

Our aim was to determine the impact of converting from tacrolimus to belatacept in patients with stable low estimated glomerular filtration rate (eGFR) early after kidney transplant.

METHODS:

This is a single-center retrospective case control study. During this study period, we had a clinical protocol to convert patients to belatacept if they had a stable but low GFR and they were at least 1-month posttransplant. Eligible patients had stable but low eGFR usually < 40 mL/min per 1.73 m. We used direct matching to select 1 control case for each patient converted to belatacept. The primary outcome was the change in eGFR from the point of belatacept conversion to 4 months postconversion (delta eGFR).

RESULTS:

There were 30 patients in the conversion group and 30 in a direct matched control group. The median preconversion eGFR for the entire cohort was 23.0 mL/min per 1.73 m with an interquartile range of 15.7 to 31.4. The delta eGFR was 11.0 (12.9) mL/min per 1.73 m in belatacept group and 4.8 (10.5) mL/min per 1.73 m in the control group (P = 0.045). Acute rejection postconversion occurred in 5 (16.7%) in the conversion group and none of the control group (P = 0.052). Although the delta improvement in eGFR was about 6 mL/min better in the Belatacept group, there was no difference in the slope of inverse creatinine during the 12-month period after conversion between the groups.

CONCLUSIONS:

We conclude that early belatacept conversion in kidney transplant recipients with stable low eGFR may only result in a modest increase in GFR.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center